Salmonella-based anti-cancer vaccine
We offer a technology of vaccine-based cancer therapy developed at the Jagiellonian University (Krakow, Poland). The immunotherapy is based on genetically modified bacterial strain of Salmonella VNP20009 that is able to target and preferentially colonise tumour tissue. Tumour targeting of VNP20009 was enhanced by single chain antibody fragments specific to carcinoembryonic antigen, which are expressed on the surface of the bacteria. Further genetic modifications were introduced to the strain to increase apoptosis and necrosis within the tumour microenvironment, resulting in augmented cancer-specific immunity. The vaccine exhibited potent efficiency in animal studies. Elimination of cancer foci by activation of the immune system is a supplement to current chemo- and radiotherapy protocols.
PL 213,066 issued 2012-08-07
WO 2,406,277 issued 2013-05-31 [MORE INFO
Type of Offer:
« More Biomedical Patents« More Medical Patents